Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel Free OCSAW Stock Alerts

Oculis (OCSAW) Competitors

Oculis logo
$2.62 +0.39 (+17.49%)
As of 12:19 PM Eastern
Compare

OCSAW vs. SXTPW, BFRIW, CALA, CINGW, and CLVR

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Clever Leaves (CLVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Oculis N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Oculis. 60 Degrees Pharmaceuticals' average media sentiment score of 1.19 beat Oculis' score of 0.89 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
Oculis Positive

Summary

60 Degrees Pharmaceuticals beats Oculis on 3 of the 3 factors compared between the two stocks.

How does Oculis compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Oculis N/A N/A N/A

In the previous week, Biofrontera had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Oculis. Biofrontera's average media sentiment score of 0.91 beat Oculis' score of 0.89 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Positive
Oculis Positive

Summary

Biofrontera beats Oculis on 3 of the 3 factors compared between the two stocks.

How does Oculis compare to Calithera Biosciences?

Oculis (NASDAQ:OCSAW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Calithera Biosciences N/A N/A N/A

In the previous week, Oculis and Oculis both had 1 articles in the media. Oculis' average media sentiment score of 0.89 beat Calithera Biosciences' score of 0.67 indicating that Oculis is being referred to more favorably in the media.

Company Overall Sentiment
Oculis Positive
Calithera Biosciences Positive

Summary

Oculis beats Calithera Biosciences on 1 of the 1 factors compared between the two stocks.

How does Oculis compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Oculis N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Oculis. Cingulate's average media sentiment score of 1.41 beat Oculis' score of 0.89 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
Oculis Positive

Summary

Cingulate beats Oculis on 2 of the 2 factors compared between the two stocks.

How does Oculis compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Oculis had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Oculis and 0 mentions for Clever Leaves. Oculis' average media sentiment score of 0.89 beat Clever Leaves' score of 0.00 indicating that Oculis is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
Oculis Positive

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Oculis N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oculis has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A
OculisN/AN/AN/AN/AN/A

Summary

Clever Leaves beats Oculis on 3 of the 5 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCSAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCSAW vs. The Competition

Export
MetricOculisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.40B$7.29B$12.91B
Dividend YieldN/A2.63%2.51%22.89%
P/E RatioN/A807.80275.6825.25
Price / SalesN/A748.52562.7878.51
Price / CashN/A86.6577.1653.04
Price / BookN/A9.1910.545.92
Net IncomeN/A$2.84B$3.50B$381.16M
7 Day Performance6.94%-4.30%-4.13%-4.32%
1 Month PerformanceN/A-8.36%-8.51%-7.19%
1 Year Performance-74.95%-6.14%2.12%-4.99%

Oculis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCSAW
Oculis
N/A$2.62
+17.5%		N/A-77.5%$0.00N/AN/A60
SXTPW
60 Degrees Pharmaceuticals
N/A$0.02
+4.2%		N/A-42.9%$0.00$1.11MN/A3
BFRIW
Biofrontera
N/A$0.01
-35.8%		N/A-94.2%$0.00$46.18MN/A94
CALA
Calithera Biosciences
N/A$0.00
flat		N/A-50.0%$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
flat		N/A-91.5%$0.00N/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OCSAW) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
Trump To Relaunch USD?
President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...
Porter & Company | Sponsoredtc pixel